All In Biotech

Drug Trial Radar · NCT02069665

Effectiveness Study of Integrative Treatment for Pediatric Pneumonia

Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by PRC National Clinical Research Base of Traditional Chinese Medicine for Major Diseases

Last checked: Nov 20, 2026Latest source record: Feb 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 451 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

451

Actual

Start

Dec 2011

Primary completion

Jul 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Liaoning University of Traditional Chinese MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing University of Chinese Medicine
First posted
Feb 24, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 months, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of traditional Chinese medicine for treatment of pediatric pneumonia. It is a multicenter randomized controlled trial.

Conditions

  • Pneumonia

Interventions

  • Fuxiong SanOther

    external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily

  • Xiyanping injectionDrug

    ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.

  • Ribavirin InjectionDrug

    ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.

  • Xiaoer Qingfei Heji (mixture)Drug

    children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;

  • Zhi Ke SanDrug

    children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

  • Hua Tan SanDrug

    children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

  • Guaifenesin SyrupDrug

    children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;

  • Ibuprofen SuspensionDrug

    taken under prescription

  • salbutamolDrug

    taken under prescription

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cured rateTime frame: Every day since receiving treatment, all together 10 days (times)
  2. Effectiveness time windowTime frame: Every day since receiving treatment, all together 10 days (times)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Children's Hospital of Capital University of Medical Sciences

    Beijing, Beijing Municipality, China

  • Guangzhou Children's Hospital

    Guangzhou, Guangdong, China

  • Affiliated Children's Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • Affiliated Hospital of Liaoning University of TCM

    Shenyang, Liaoning, China

  • Affiliated Hospital of Shandong University of TCM

    Ji'nan, Shandong, China

  • Affiliated Longhua Hospital of Shanghai University of TCM

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.